This course has expired. You can still review the content but course credit is no longer available.
Supported by an educational grant from Allergan plc
Upon completion of this activity, the participant should be able to:
• Discuss current pathogenic mechanisms of Alzheimer’s disease and rule out other causes of dementia.
• Assess the epidemiology and risk factors for developing dementia.
• Evaluate the diagnosis of people with mild cognitive impairment and dementia associated with Alzheimer’s disease.
• Formulate treatment options for patients with Alzheimer’s disease, including MCI and dementia.
• Formulate strategies to best prevent further cognitive decline.
• Discuss beneficial interventions for caregivers, AD patients and their families.
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following faculty members have the following financial relationships with commercial interests:
Alireza Atri, MD has has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan plc; Axovant Sciences Ltd.; Biogen, Inc.; Grifols, S.A.; Lundbeck Inc.; and Sunovion Pharmaceuticals Inc. Grant/Research Support: AbbVie Inc.; American College of Radiology; Avid Radiopharmaceuticals Inc; Biogen, Inc.; Eli Lilly and Company; Lundbeck Inc.; and vTv Therapeutics. Other Financial Support: Oxford University Press (UOP) for Book Royalties.
Pierre N. Tariot, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Acadia Pharmaceuticals; Abbott Laboratories, AbbVie Inc.; AC Immune, AstraZeneca; Auspex Pharmaceuticals; Avanir Pharmaceuticals; Boehringer-Ingelheim, Brain Test Inc., California Pacific Medical Center, Chase Pharmaceuticals, CME Inc., Eli Lilly and Company; GliaCure, H. Lundbeck A/S; Issy Therapeutics, Merck & Co.; Pfizer, Inc.; Roche Pharma; Takeda Pharmaceuticals U.S.A., Inc.; and T3D. Grant/Research Support: Acadia Pharmaceuticals; Amgen Inc.; AstraZeneca; Avanir Pharmaceuticals; Avid Radiopharmaceuticals, Inc.; Biogen,Inc.; Elan Corporation plc; Eli Lilly and Company; Functional Neuromodulation; GE; Genentech Genentech, Inc.; H. Lundbeck A/S; Merck & Co.; Pfizer, Inc.; Novartis Pharmaceuticals; Roche Pharma; Takeda Pharmaceuticals U.S.A., Inc.; and Tagamet Inc. Stock/Shareholder: Adamas Pharmaceuticals. Other: Alzheimer’s Association; Banner Alzheimer’s Foundation; Arizona Department of Health Services; FBRI; Flinn Foundation; Geoffrey Beene Foundation; GHR; National Institute on Aging (RF1 AG041705, 1UF1AG046150, R01 AG031581, R01 AG055444, P30 AG19610); Nomis Foundation; and Patents Contributor to a patent owned by the University of Rochester, “Biomarkers of Alzheimer’s Disease”.
Editorial Support Disclosures
Cheryl Cavanaugh, MS, Evolve Medical Education LLC; Katherine L. Molnar-Kimber, Ph.D. Writer; and Diler Acar, MD, Peer Reviewer; have no real or apparent conflicts of interest to report.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC and Allergan plc.